1246765-27-4

Basic information

• Product Name: methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate
• Synonyms: methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate;Methyl 2-Methoxy-6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl);3-Pyridinecarboxylic acid, 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester
• CAS NO: 1246765-27-4
• Molecular Formula: C₁₄H₂₀BNO₅
• Molecular Weight: 293
• Mol File: 1246765-27-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate(1246765-27-4)
• EPA Substance Registry System: methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate(1246765-27-4)

Safety Data

• Hazardous Substances Data: 1246765-27-4(Hazardous Substances Data)

Usage

General Description

Methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate is a chemical compound commonly used in the field of organic synthesis. It is a derivative of nicotinic acid, also known as niacin, and contains a methyl and methoxy group on the second and sixth carbon atoms of the nicotinate ring, respectively. The compound also features a boronate ester functional group, which is often used in cross-coupling reactions to form carbon-carbon bonds. Methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate has shown potential as a building block in the synthesis of pharmaceuticals, agrochemicals, and materials.

Upstream product

• 65515-32-4 methyl 6-chloro-2-methoxypyridine-3-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 67367-26-4 2-methoxynicotinic acid methyl ester 
• 65515-28-8 methyl 2,6-dichloronicotinate 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 

Downstream Products

• 1246765-51-4 methyl 6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinate 
• 1246765-52-5 (R)-methyl 6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinate 
• 1246765-54-7 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid 
• 1350884-15-9 C₁₆H₁₆N₂O₆ 
• 1246766-21-1 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy-N-(1H-tetrazol-5-yl)nicotinamide 
• 1246766-25-5 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy-N-(methylsulfonyl)nicotinamide 
• 1246766-15-3 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy-N,N-dimethylnicotinamide 
• 1246766-12-0 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy-N-methylnicotinamide 

Relevant articles and documents

Iridium-catalyzed C-H borylation of pyridines

The iridium-catalysed C-H borylation is a valuable and attractive method for the preparation of aryl and heteroaryl boronates. However, application of this methodology for the preparation of pyridyl and related azinyl boronates can be challenged by low reactivity and propensity for rapid protodeborylation, particularly for a boronate ester ortho to the azinyl nitrogen. Competition experiments have revealed that the low reactivity is due to inhibition of the active catalyst through coordination of the azinyl nitrogen lone pair at the vacant site on the iridium. This effect can be overcome through the incorporation of a substituent at C-2. Moreover, when this is sufficiently electron-withdrawing protodeborylation is sufficiently slowed to permit isolation and purification of the C-6 boronate ester. Following functionalization, reduction of the directing C-2 substituent provides the product arising from formal ortho borylation of an unhindered pyridine ring. This journal is the Partner Organisations 2014.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.